Supernus Pharmaceuticals has agreed to acquire Sage Therapeutics for approximately $561 million upfront, plus contingent value rights potentially increasing the deal to $795 million. The acquisition centers on Sage's FDA-approved postpartum depression drug Zurzuvae, which has shown promising sales growth despite Sage’s prior struggles and layoffs. Supernus aims to integrate Zurzuvae as a key growth product alongside its existing CNS treatments. Analysts view the transaction as a moderate resolution for Sage after challenging years but acknowledge the strategic fit for Supernus. The deal is expected to close in the third quarter of 2025.